Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aridis Pharmaceuticals (ARDS)
OTHER OTC:ARDS
Aridis Pharmaceuticals (ARDS) Stock Price & Analysis
207 Followers
ARDS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.03 - $0.30
Previous Close$0.06
Volume168.44K
Average Volume (3M)95.85K
Market Cap
$2.89M
Enterprise Value$7.70M
Total Cash (Recent Filing)$35.00K
Total Debt (Recent Filing)$4.84M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Aug 13, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding44,574,021
10 Day Avg. Volume89,976
30 Day Avg. Volume95,850
Standard Deviation0.32
R-Squared0.04
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-0.30
Price to Sales (P/S)1.14
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.34
Enterprise Value/Gross Profit2.49
Enterprise Value/Ebitda0.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Aridis Pharmaceuticals News
Ownership Overview
5.14% Insiders
1.87% Mutual Funds
<0.01% Other Institutional Investors
92.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARDS FAQ
What was Aridis Pharmaceuticals’s price range in the past 12 months?
Aridis Pharmaceuticals lowest stock price was $0.03 and its highest was $0.29 in the past 12 months.
What is Aridis Pharmaceuticals’s market cap?
Currently, no data Available
When is Aridis Pharmaceuticals’s upcoming earnings report date?
Aridis Pharmaceuticals’s upcoming earnings report date is Aug 13, 2024 which is in 26 days.
How were Aridis Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Aridis Pharmaceuticals overvalued?
According to Wall Street analysts Aridis Pharmaceuticals’s price is currently Overvalued.
Does Aridis Pharmaceuticals pay dividends?
Aridis Pharmaceuticals does not currently pay dividends.
What is Aridis Pharmaceuticals’s EPS estimate?
Aridis Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aridis Pharmaceuticals have?
Aridis Pharmaceuticals has 44,574,020 shares outstanding.
What happened to Aridis Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aridis Pharmaceuticals?
Currently, no hedge funds are holding shares in ARDS
---
Aridis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
---
ARDS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Arcturus Therapeutics
―
Eloxx Pharmaceuticals
―
Cidara Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering ARDS
1 Year
1 Year Success Rate
1/19 ratings generated profit
1 Year Average Return
-59.97%
reiterated a buy rating 9 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 5.26% of your transactions generating a profit, with an average return of -59.97% per trade.
---